Cyagen at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Cyagen brings 3 presentations to ESGCT 2026 in Hamburg. Its contribution covers preclinical models and vectors. Work includes humanised-gene mouse models for testing nucleic acid therapies and neurological research, and an AAV2 variant that spreads expression across the retina after injection into the eye in monkeys.
| Organization | ESGCT 2026 Attendance |
|---|---|
Contract research provider of genetically engineered animal models, custom cell lines, and AAV, lentivirus and adenovirus packaging for preclinical research. | Poster Wed Oct 28 1:30pm–3:30pm A new AAV2 variant, PN168, achieves cross-retinal transgene expression following intravitreal (IVT) injection in non-human primates (NHPs) Poster Wed Oct 28 1:30pm–3:30pm Advancing Neurological Research: Mouse Models with Humanized Genes as Tools for Understanding Pathophysiology and Therapeutics Poster Thu Oct 29 2:00pm–4:00pm HUGO-GT™ (HUmanized Genomic Ortholog) mouse models enable translational preclinical preclinical validation of nucleic acid therapeutics RNA and oligonucleotide therapies |
Instantly find 20 buyers from Cyagen
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction